- Home
- WYY vs FBLG Comparison
WYY vs FBLG Comparison
Compare WYY & FBLG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYY
- FBLG
- Stock Information
- Founded
- WYY 1991
- FBLG 2021
- Country
- WYY United States
- FBLG United States
- Employees
- WYY N/A
- FBLG N/A
- Industry
- WYY EDP Services
- FBLG
- Sector
- WYY Technology
- FBLG
- Exchange
- WYY Nasdaq
- FBLG NYSE
- Market Cap
- WYY 35.6M
- FBLG 37.1M
- IPO Year
- WYY 1998
- FBLG 2024
- Fundamental
- Price
- WYY $5.47
- FBLG $0.83
- Analyst Decision
- WYY Strong Buy
- FBLG Strong Buy
- Analyst Count
- WYY 1
- FBLG 4
- Target Price
- WYY $7.00
- FBLG $13.00
- AVG Volume (30 Days)
- WYY 83.5K
- FBLG 225.7K
- Earning Date
- WYY 05-15-2025
- FBLG 05-16-2025
- Dividend Yield
- WYY N/A
- FBLG N/A
- EPS Growth
- WYY N/A
- FBLG N/A
- EPS
- WYY N/A
- FBLG N/A
- Revenue
- WYY $142,571,749.00
- FBLG N/A
- Revenue This Year
- WYY $10.84
- FBLG N/A
- Revenue Next Year
- WYY $12.37
- FBLG N/A
- P/E Ratio
- WYY N/A
- FBLG N/A
- Revenue Growth
- WYY 34.47
- FBLG N/A
- 52 Week Low
- WYY $2.19
- FBLG $0.76
- 52 Week High
- WYY $6.25
- FBLG $13.59
- Technical
- Relative Strength Index (RSI)
- WYY 83.82
- FBLG 37.29
- Support Level
- WYY $4.78
- FBLG $0.95
- Resistance Level
- WYY $5.24
- FBLG $0.93
- Average True Range (ATR)
- WYY 0.47
- FBLG 0.13
- MACD
- WYY 0.21
- FBLG -0.03
- Stochastic Oscillator
- WYY 98.88
- FBLG 5.49
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically the company generates a majority of its revenue from the United States and rest from Europe.
About FBLG FIBROBIOLOGICS INC
FibroBiologics Inc is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing, and certain cancers, and potential extension of life applications including thymic and splenic involution reversal.